Autem Therapeutics

Key People

• Michael Choukas - Chief Executive Officer
  Email: info@autemtherapeutics.com

Assessment

Team

Aspect: First-time 10+ yrs
Summary: Experienced leadership with a strong track record in life sciences.

CEO Michael Choukas brings extensive experience in life sciences, having held leadership roles in companies like United BioSource, Oncopartners, Vector Oncology, and Concerto HealthAI. His background suggests a strong capability to lead Autem Therapeutics effectively.

Clinical Need

Aspect: Very Strong
Summary: High unmet need in treating advanced hepatocellular carcinoma (HCC).

HCC is a leading cause of cancer-related deaths worldwide, with limited effective treatment options. Autem's non-invasive, non-toxic therapy addresses this significant unmet need, potentially improving patient outcomes and quality of life.

Competition

Aspect: First mover
Summary: Pioneering bioelectric therapy in oncology with limited direct competition.

Autem Therapeutics is among the first to develop a bioelectric oncology treatment platform targeting HCC, positioning itself as a first mover in this innovative therapeutic area. This unique approach may provide a competitive advantage in the market.

Technical Challenge

Aspect: Moderate
Summary: Developing and validating bioelectric therapy presents moderate technical challenges.

While the concept of bioelectric therapy is promising, developing and clinically validating such a novel treatment involves moderate technical challenges, including ensuring consistent efficacy, safety, and regulatory compliance.

Patent

Aspect: Applied
Summary: Patent status not specified; assumed to be in application stage.

The available information does not specify the patent status of Autem's technology. Assuming patents have been applied for, this would provide a level of protection for their proprietary therapy, contributing to the company's competitive position.

Financing

Aspect: Well-funded
Summary: Secured $10 million Series A-1 financing led by Zentynel Frontier Investments.

In June 2022, Autem Therapeutics completed a $10 million Series A-1 financing round led by Zentynel Frontier Investments. This funding supports the development of their AutEMsys technology and the initiation of pivotal clinical trials.

Regulatory

Aspect: Pivotal Trial
Summary: Received FDA Breakthrough Therapy Designation; planning pivotal trials.

Autem Therapeutics has received FDA Breakthrough Therapy Designation for its AutEMsys therapy for advanced HCC patients. The company plans to submit an Investigational Device Exemption (IDE) to initiate pivotal clinical trials, indicating progress in the regulatory pathway.

Opportunity Rollup

Odds of Success

3.95

Peak Market Share

5.85

Segment CAGR

<em>Unknown</em>

Market Segment

Oncology Therapeutics

Market Sub Segment

Hepatocellular Carcinoma Treatment

Key Takeaway

Autem Therapeutics is well-positioned to address a significant unmet need in HCC treatment with its innovative bioelectric therapy, supported by experienced leadership and recent funding, though it faces moderate technical and regulatory challenges.